key: cord-0993971-pho0sbky
authors: Pan, Feng; Yang, Lian; Liang, Bo; Ye, Tianhe; Li, Lingli; Li, Lin; Liu, Dehan; Wang, Jiazheng; Hesketh, Richard L.; Zheng, Chuansheng
title: Chest CT Patterns from Diagnosis to 1 Year of Follow-up in COVID-19
date: 2021-10-05
journal: Radiology
DOI: 10.1148/radiol.2021211199
sha: 3cc85d104cd97791d1742ac6e4d2d20bfaec9e3d
doc_id: 993971
cord_uid: pho0sbky

BACKGROUND: The chest CT manifestations of COVID-19 from hospitalization to convalescence after one year are not known. PURPOSE: To assess chest CT manifestations of COVID-19 up to 1 year after symptom onset. MATERIALS AND METHODS: Patients were enrolled if they were admitted to the hospital due to COVID-19 and underwent CT scans during hospitalization at two isolation centers between 27 January and 31 March 2020. In a prospective study, three serial chest CTs were obtained at approximately 3, 7, and 12 months after symptom onset and longitudinally analyzed. The total CT score of pulmonary lobe involvement from 0 to 25 was assessed (score 1-5 for each lobe). Uni-/multi-variable logistic regression tests were performed to explore independent risk factors for residual CT abnormalities after one year. RESULTS: 209 study participants (mean age: 49±13 years, 116 women) were evaluated. At 3 months, 61% of participants (128 of 209) had resolution of CT abnormalities; at 12 months, 75% (156 of 209) had resolution. Of chest CT abnormalities that had not resolved, there were residual linear opacities in 25/209 (12%) and multifocal reticular/cystic lesions in 28/209 (13%) participants. Age≥50 years, lymphopenia, and severe/ARDS aggravation were independent risk factors for residual CT abnormalities at one year (odds ratios of 15.9, 18.9, and 43.9, respectively; P<.001, each). In 53 participants with residual CT abnormalities at 12 months, reticular lesions (41 of 53, 77%) and bronchial dilation (39 of 53, 74%) were observed at discharge and were persistent in 53% (28 of 53) and 45% (24 of 53) of participants, respectively. CONCLUSION: One year after COVID-19 diagnosis, chest CT showed abnormal findings in 25% of participants, with 13% showing subpleural reticular/cystic lesions. Older participants with severe COVID-19 or acute respiratory distress syndrome were more likely to develop lung sequelae that persisted at 1 year. See also the editorial by Lee and Wi.

Since the global outbreak of the COVID-19 pandemic, more than a hundred million people have been infected, resulting in over three million deaths globally [1] . Several of the beta coronaviruses have many similarities in their clinical course, laboratory, radiological, and pathological features. These coronaviruses include severe acute respiratory syndrome (SARS), Middle East respiratory syndrome and COVID-19. [2] [3] [4] [5] . However, SARS-CoV2 has proven more contagious than other coronaviruses, thus resulting in a far higher number of cases and a global pandemic [1, 6] .

Previous chest CT observations of COVID-19 have demonstrated a typical radiological course from initial bilateral and subpleural ground-glass opacities (GGOs) to a more extensive consolidation, with slow but gradual absorption of the lung lesions in survivors [7] [8] [9] [10] [11] . However, residual pulmonary lesions such as GGOs and parenchymal bands have been observed in more than ninety percent of patients at hospital discharge [7, 9] . Because coronavirus infection can result in diffuse alveolar exudation and lead to fatal acute respiratory distress syndrome (ARDS), post-infection sequelae such as lung fibrosis are a concern [12, 13] . Focal lung fibrosis in chest CT has been observed in patients who have recovered from SARS, even after a 7-year follow-up [14, 15] . Although lung lesions mostly resolve in COVID-19 with mild to moderate severities, an autopsy study has confirmed lung organization and fibrosis in patients with fatal COVID-19, raising the possibility of permanent lung fibrosis sequelae in survivors with severe infection [7, 16] . In some patients with COVID-19, fibrotic sequelae including traction bronchiectasis, parenchymal bands, and "honeycombing" have been observed in more than one-third of participants with severe COVID-19 six months after symptom onset [7, 17] . However, it is unknown whether or not COVID-19 survivors develop lung fibrosis after a long follow-up period and if risk factors at presentation are predictive of long-term loss of function. If so, chest CT could potentially identify participants that might benefit from early anti-fibrotic therapy [18] . The purpose of our study was to evaluate serial chest CT examinations for the one-year temporal evolution of radiological findings after COVID-19 infection.

This study was approved by the Ethics of Committees of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (No. 2020-0026) and followed the 1964 Helsinki Declaration and its later amendments. Informed consent was obtained from all study participants.

We prospectively evaluated participants with COVID-19 consecutively discharged from two isolation centers (Western Campus and Zhuankou Fangcang Shelter Hospitals, affiliated to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) between 27 January and 31 March 2020. This cohort included participants reported in a previous study only involving data at admission and discharge for the longitudinal analysis in our study [7] . The criteria of diagnosis, therapy, and discharge followed the nationally standardized protocols [19] . Patients with respiratory rate >30 breaths/min or oxygen saturation (SpO2) ≤93% on room air were classified as severe COVID-19, while ARDS was diagnosed with arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FIO2) ≤300 mmHg [19] [20] [21] . The inclusion criteria were as follows: 1. Age ≥18 years; 2. No medical history of pulmonary, autoimmune, or malignant disease; 3. COVID-19 survivors who underwent hospitalized treatment; 4. Chest CT performed at admission and discharge; 5. Chest CT at discharge demonstrated residual lung lesions related to COVID-19; 6. Gave voluntary, written informed consent for chest CT follow-up. Participants that dropped out of the study had a subsequent positive COVID-19 nucleic acid test or acquired an additional lung infection following discharge were excluded.

Non-contrast chest CT examinations were performed using the same commercial CT scanner (Philips Ingenuity Core128, Philips Medical Systems). Images were obtained during breath-holding at full inspiration. The fixed tube voltage was set to 120kVp with adaptive current modulation resulting in a volume CT dose index of 7.1±2.2 mGy (range: 3.1-12.2 mGy) and a dose length product of 286.0±97.2 I n p r e s s mGy•cm (range: 99.2-506.3 mGy•cm). Other acquisition parameters included a pitch of 0.999, collimation of 64×0.625 mm, a gantry rotation time of 0.75 s, and a DoseRight index of 18. From the raw data, axial CT images were reconstructed with a matrix size of 512 × 512 (thickness of 1.5 mm and interval of 1.5 mm) using iterative reconstruction (iDose level 5, Philips Healthcare).

Chest CT data at admission and discharge were retrospectively collected from the institutional PACS system (Vue PACS, version 11.3.5.8902; Carestream Health). In addition, three serial chest CT examinations were carried out after 3-, 7-, and 12-month periods since initial symptom onset. Visual assessments were performed by three senior radiologists (C.Z, B.L. and L.Y., with 27, 26 and 23 years of clinical experience in thoracic radiology, respectively) independently. Afterwards, any disagreement was resolved by discussion and consensus. Three radiologists were blinded to the clinical progress of all participants. Abnormalities were described using the standard terminology defined in the Fleischner Society glossary and peer-reviewed literature ( Figure E1) [7, 8, 11, 17, [22] [23] [24] . Complete resolution was defined as the disappearance of any lung abnormalities on chest CT related to COVID-19 [7] . The distribution of lung lesions was categorized as a subpleural, diffuse, or random distribution [8] . Following the methods in previous studies of COVID-19, we used the same semi-quantitative CT score system to estimate the involvement of the lung lesions in each lobe from 0 to 5 points: 0, no lesion; 1, <5%; 2, 5% to 25%; 3, 26% to 49%; 4, 50%-75%; 5. >75% [8, 17, 25] . The sum of the CT score in each lobe was calculated as the total CT score ranging from 0 to 25. At 12 months after symptom onset, participants with or without residual CT abnormalities were compared.

All statistical analysis was performed using IBM SPSS Statistics Software (version 26; IBM).

Quantitative and counting data were presented as mean ± standard deviation with range and the percentage of the total, respectively. Mann-Whitney tests were performed to estimate continuous I n p r e s s variables between different groups according to the non-normal distribution assessed by the Shapiro-Wilk tests. Chi-square tests were performed to evaluate categorical variables between different groups. Fisher's exact test was performed instead of Chi-square test if expected count less than five. Univariable and multivariable logistic regression tests (Forward Conditional Method) were used to investigate the independent risk factors for chronic CT changes after 1 year and odds ratio (OR) with 95% confidence interval (95%CI) was calculated. Linear mixed models of repeated measures were established to estimate the fixed effects of the time and participant grouping on the number of involved lung lobes and total CT score by using Type III tests. Further inter-time point comparisons were performed by using Bonferroni adjustments. A statistical significance was defined at a P value <.001 level (two-tailed).

Characteristics of Study Sample 2171 patients discharged from the hospital were screened for our study, of which 209 participants were included in the final analysis. 1063 patients were excluded owing to the lack of chest CT at admission, and 285 patients were excluded due to complete resolution of CT abnormalities at discharge (Figure 1 ).

In the follow-up, 15 and 3 participants were excluded owing to study dropout and occurrence of secondary lung infection, respectively (Figure 1) . The average age of participants was 49±13 years (range: 20-82 years) with a 1:1.25 male-to-female ratio. 20% of participants (41/209) had prior comorbidities, including hypertension, type-II diabetes mellitus and coronary heart disease. 4 participants (4/209, 1.9%) had a history of smoking. The mean interval between symptom onset and admission was 6.9±4.4 days (range: 1.0-18.0 days). 107 (51%), 80 (38%), and 22 (11%) participants were diagnosed with pneumonia, severe pneumonia, and ARDS, respectively. All participants who developed ARDS received mechanical ventilation therapy in an intensive care unit. The mean hospitalized period was 24.8±13.3 days (range: 5.0-80.0 days). The chest CT examinations at admission and discharge were performed at 6.3±4.5 days and 28.3±13.8 days after symptom onset, respectively. The detailed information is summarized in Table 1 .

The complete resolution rate gradually increased over time from 61% (128/209) at 3 months to 75% (156/209) at 12 months after symptom onset (Figure 2a and Table E1 ). At admission GGOs (201/209, 96%), consolidation (124/209, 59%) and crazy-paving (53/209, 25%) were the most common findings (Figure 2b and Table E1 ). Thereafter, consolidation and crazy-paving gradually improved over time, whereas other pulmonary abnormalities, including GGOs, parenchymal bands, reticular lesions, bronchial dilation and volume loss, tended to increase after admission but start to resolve after discharge (Figure 2b and Table E1 ). However, at 3 months after symptom onset, CT abnormalities had stabilized except for GGOs and parenchymal bands, which gradually resorbed (Figure 2b and Table E1 ). Nevertheless, GGOs were the predominant radiological pattern throughout (Figure 2c and Table E1 ). The mean total CT score and the number of involved lung lobes gradually decreased from admission (9.7±7.0 and 3.7±1.5) to 12 months (1.8±3.9 and 0.9±1.7) after symptom onset (P<.001, both) (Figure 2d and Table E1 ). After 3 months, the decrease in mean total CT score and mean number of involved lung lobes became nonsignificant (P≥.33 and P ≥.06, respectively) (Figure 2d ).

Participants were divided into two groups based on the CT abnormalities at 12 months after symptom onset: participants with complete resolution (156/209, 75%) ( Figure 3 ) and participants with residual CT abnormalities (53/209, 25%) (Figure 4 and 5) . In participants with complete resolution, no recurrent pulmonary abnormalities were observed in further follow-up after complete resolution was initially achieved (Figure 3) . Age, prior comorbidities, COVID-19 severities, time of admission from symptom onset, hospitalized period, lymphocyte count, lactate dehydrogenase, albumin, number of involved lobes and total CT score at admission all demonstrated differences between the two groups (P≤.001, each) ( Table 2 and Table 3 ). Age ≥ 50 years, lymphopenia and severe/ARDS aggravation were independent I n p r e s s risk factors for residual CT abnormalities at one year (odds ratios of 18.9, 15.9 and 43.9, respectively; P<.001, each) ( Table 4) .

Diffuse consolidation was more common on chest CT at admission and discharge in participants with residual CT abnormalities than with complete resolution ( Table 3) . At discharge, complicated CT abnormalities including reticular lesions, bronchial dilation and volume loss were more commonly observed in participants with residual CT abnormalities than participants with complete resolution, whilst predominant GGO was common to both groups ( Table 3) . Over time, the total CT score and number of involved lung lobes gradually decreased with significant improvements at 3 months ( Figure 6 ) but were higher in participants with residual CT abnormalities than participants with complete resolution (Table   E2 ). Noticeably in participants with complete resolution, reticular lesions (21/156, 14%) and bronchial dilation (18/156, 12%) were observed at discharge but had almost completely resorbed at 3 months ( Figure 6 and E2). In participants with residual CT abnormalities, reticular lesions (41/53, 77%) and bronchial dilation (39/53, 74%) observed at discharge were incompletely resorbed and persisted in 53% (28/53) and 45% (24/53) of participants at 12 months, respectively (Figure 4-6 ).

Based on the different residual CT abnormalities at 12 months, participants could be further divided into two subgroups (Table E3) : participants with residual linear opacities (25/53, 47%) and with multifocal reticular/cystic lesions (28/53, 53%). Participants with residual linear opacities demonstrated gradual resolution of pulmonary lesions since discharge, leaving residual parenchymal bands or thin linear opacities (Figure 4 , E3, E5 and Table E4 ). In contrast, participants with multifocal reticular/cystic lesions presented persistent subpleural reticular or cystic lesions in the follow-up ( Figure 5 , E4, E5 and Table E4 ). At 12 months, the total CT score was 3.9±2.6 vs. 10.1±4.3, and the number of involved lung lobes was 2.6±1.0 vs. 4.5±1.2 in participants with residual linear opacities and multifocal reticular/cystic I n p r e s s lesions, respectively (P<.001, both) ( Table E3 and E4). However, the improvements of total CT scores in both subgroups were observed at 3 months after symptom onset (P<.001) ( Figure E5 ).

This study analyzed the chest CT patterns of 209 participants with COVID-19 over one year following symptom onset. Based on the CT findings at 12 months, participants could be categorized into three Similar to previous reports, bilateral subpleural GGOs with partial consolidation and GGOs with parenchymal bands were the most frequent CT findings at admission and discharge, respectively [7] [8] [9] 11] .

Any consolidation at admission had been gradually absorbed, typically with a "melting sugar" pattern of resorption whereby the density of consolidation gradually decreases to GGO but the lesion volume initially enlarges [7, 17] . After 1 year, complete resolution was observed in 98% of participants with moderate pneumonia (105 of 107) but only in 50% of participants with severe pneumonia or ARDS (51 of 102) (P<.001), corroborating the findings of a previous study [7] . We found that old age, lymphopenia, and severe/ARDS aggravation, which correlated with mortality, were risk factors of residual CT abnormalities [4, 10, 26, 27] . The presence of multifocal reticular/cystic lesions at discharge was persistent in 28 participants and accompanied by bronchial dilation in 24 of them (24/28, 86%). Although some I n p r e s s articles prompted a potential correlation between mechanical ventilation and these changes, we observed that a high proportion of these participants (12/28, 43%) did not undergo mechanical ventilation therapy [12, 17, 28, 29] . So, our results suggest multiple factors contribute to the development of these interstitial lesions, and mechanical ventilation and ARDS are not the only factors.

In a previous study involving 114 participants with severe COVID-19, residual CT abnormalities (including GGO, bronchial dilation, parenchymal bands, and honeycombing) were observed in 62% of recovered participants (71 of 114) after 6 months [17] . These CT abnormalities were the typical manifestations of interstitial fibrosis [22,30,31]. Our study found a lower rate of 25% (53 of 209) of participants demonstrated CT abnormalities after 1 year [17] . Several reasons could explain this difference. First, the previous study only included severe COVID-19, but we had participants with different severities [17] . However, the number of severe pneumonia or ARDS participants was similar between the two studies (83 vs. 80 and 31 vs. 22, respectively) [17] . Second, we excluded participants with prior chronic lung disease; their inclusion in the previous study may lead to misjudgments of the lung sequelae not genuinely caused by COVID-19. As a potential indicator of this, predominant reticular lesions (14%), bronchiectasis (11%), and honeycombing (1.8%) at admission were reported previously, which we did not corroborate. Our study also found that focally subpleural reticular/cystic lesions and bronchial dilation could be observed at discharge in 30% of the participants (62/209) but resolved in more than half of participants within the first 3 months, indicating remodeling of immature fibrosis [12, 23] .

Reversal of these CT abnormalities has also been observed in SARS, other diffuse alveolar damage, and organizing pneumonia [23,32,33]. Similar to the findings in SARS, we observed persistent but very focally reticular or cystic lesions only in a small portion of participants with severe COVID-19 and ARDS [15] . However, the differentiation of true, irreversible fibrosis from reversible lesions is far from straightforward, and the limited follow-up period in previous studies might result in the overdiagnosis of fibrosis [13, 34, 35] . For these reasons, we avoided radiological terms such as "traction bronchiectasis", "honeycombing", and "reticular pattern" for their association with genuine lung fibrosis. Instead, we used I n p r e s s the term "bronchial dilation", "subpleural cystic lesions", and "reticular lesions", which were reported to be partially reversible [12, 17, 22, 24] .

Our study has limitations. First, there were selection biases. Thousands of discharged participants were excluded due to a lack of chest CT data at admission. The high mortality of critically ill participants with with rare smoking history (1.9%) was reported. While our approach permitted lung abnormalities to be more definitively attributed to COVID-19, we may underestimate the long-term impact of COVID-19 on the general population, especially on old patients and patients with a smoking history or prior lung diseases who probably have more common or more severe lung sequelae [37] . Second, it is unknown whether these CT abnormalities will regress after a longer follow-up meriting further clinical and radiological follow-up. However, considering residual lesions rarely change after 1 year in SARS, these CT abnormalities in COVID-19 are likely permanent [15, 38] . Third, systematic use of pulmonary function testing was not performed, owing to use restrictions during the pandemic. This limits our understanding of the functional consequences of CT findings.

In conclusion, one year after COVID-19 diagnosis, three chest CT patterns including complete resolution, residual linear opacities and multifocal reticular/cystic lesions could be observed, with complete resolution being the most common. Some of the fibrotic lung changes demonstrated at discharge partially resorbed over time, predominantly between discharge and 3 months following the onset of symptoms. Note: Quantitative data were presented as mean ± standard deviation with a range in parentheses. Counting data were presented as numbers of participants with a percentage of the total in parentheses. The normal reference values of laboratory investigations were provided in parentheses. Note: Participants were divided into two groups: complete resolution at 12 months (n=156) and residual CT abnormalities at 12 months (n=53). Quantitative data were presented as mean±standard deviation with a range in parentheses unless specifically indicated. Counting data were presented as numbers of participants with a percentage of the total in parentheses. P values comparing participants with complete resolution and participants with residual CT abnormalities were determined using the Mann-Whitney U test or Chi-square test. Graphs showed significant differences of percentage of reticular lesions (c) and bronchial dilation (d) between two subgroups at 3-, 7-, and 12-month time points by using Chi-square and Fisher's exact tests (P<.001, each). Linear mixed model of repeated measures was established to estimate the fixed effects of the time and grouping on the total CT score (a) and the number of involved lung lobes (b) using Type III tests, and P values of multiple comparisons were performed by using Bonferroni adjustments. The significant decreases of mean total CT score (a) and number of involved lung lobes (b) in both subgroups were seen at 3 months (P<.001, each). Overtime the total CT score (a) and the number of involved lung lobes (b) gradually decreased but were higher in participants with multifocal reticular/cystic lesions compared with participants with residual linear opacities (P<.001, both). I n p r e s s Consolidation 0 (0.0) 3 (11) .24

Parenchymal bands 25 (100) 28 (100) 1.00 Participants were divided into two subgroups: residual linear opacities (n=25) and multifocal reticular/cystic lesions (n=28) at 12 months. Quantitative data were presented as mean ± standard deviation with a range in parentheses unless specifically indicated. Counting data were presented as numbers of participants with a percentage of the total in parentheses. P values comparing participants with residual linear opacities and participants with multifocal reticular/cystic lesions were determined using the Mann-Whitney U test, Chi-square test, or Fisher exact test. OR = odds ratio, 95%CI = 95% confidence interval. * The values of odds ratios were shown with 95% confidence intervals in parentheses. 

Weekly epidemiological update on Coronavirus disease (COVID-19) -4

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SARS and other coronaviruses as causes of pneumonia

Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV

The pulmonary sequalae in discharged patients with COVID-19: a short-term observational study

Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19)

Temporal Changes of CT Findings in 90 Patients with COVID-19

Pneumonia: A Longitudinal Study

Different computed tomography patterns of Coronavirus Disease 2019 (COVID-19) between survivors and non-survivors

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Interstitial Lung Disease after COVID-19 Infection: A Catalog of Uncertainties

Pulmonary fibrosis secondary to COVID-19: a call to arms?

SARS: prognosis, outcome and sequelae

Thin-Section Computed Tomography Manifestations During Convalescence and Long-Term Follow-Up of Patients with Severe Acute Respiratory Syndrome (SARS)

Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID-19 pneumonia in Wuhan, China

Six-month Follow-up Chest CT Findings after Severe

Follow-up studies in COVID-19 recovered patients -is it mandatory?

National Health Commission of the People's Republic of China. Diagnosis and treatment protocols of pneumonia caused by a novel coronavirus

Linear mixed model of repeated measures was established to estimate the fixed effects of the time on the number of involved lung lobes and CT score using Type III tests

We appreciate the fund supports from Huazhong University of Science and Technology and Ministry of Science and Technology, China. Besides, we would like to express our sincere gratitude to the emergency services, nurses, doctors, and medical support from other provinces for their efforts to combat the COVID-19 outbreak in Wuhan.